昆明在哪家医院做人流较好云南台俪电话号码查询,台俪哪家好,昆明正规打胎多钱,昆明哪个打胎医院比较好,昆明市台俪医院做引流多少钱,昆明怀孕27天打胎多少钱,昆明市妇幼在线咨询

BEIJING, July 26 (Xinhuanet) -- Seven of the 20 top selling American prescription drugs will lose their patents by the end of next year, making way for less expensive generic versions, according to media reports.It's a shift that could save consumers billions of dollars -- assuming those big-ticket medications are willing to give up a trusted brand name for an off-label replacement.The prices of medications such as cholesterol-fighting Lipitor and blood thinner Plavix are expected to go down significantly, according to the U.S. Food and Drug Administration (FDA).Lipitor will lose its patent in November. When that patent expires, people are advised to buy atorvastatin, the generic equivalent. Other brand names include the anti-psychotic Zyprexa and the rheumatoid arthritis and psoriasis drug Enbrel, of which the patent will expire in October and October of next year, respectively.Over the next 10 years, an estimated 120 more brand-name prescription drugs will lose their patents in the U.S.

SAN FRANCISCO, Aug. 15 (Xinhua) --- Google Inc. on Monday announced that it has agreed to buy Motorola Mobility Holdings Inc. for about 12. 5 billion U.S. dollars, the largest purchase for the Internet search giant that will allow it to compete more directly with other mobile phone makers.Google said that it will acquire Motorola Mobility for 40 dollars per share in cash, or a total of about 12.5 billion dollars, a premium of 63 percent to the closing price of Motorola Mobility shares last Friday.The transaction was unanimously approved by the boards of directors of both companies and is expected to close by the end of 2011 or early 2012, subject to regulatory approvals and other closing conditions.Google noted that the acquisition of Motorola Mobility, a dedicated partner of its Android mobile operating system, will enhance competition in mobile computing.Motorola Mobility will remain a licensee of Android and Android will remain open, Google said, adding that it will run Motorola Mobility as a separate business."Motorola Mobility's total commitment to Android has created a natural fit for our two companies. Together, we will create amazing user experiences that supercharge the entire Android ecosystem for the benefit of consumers, partners and developers," Larry Page, Google's chief executive officer (CEO), said in a statement."We have shared a productive partnership with Google to advance the Android platform, and now through this combination we will be able to do even more to innovate and deliver outstanding mobility solutions across our mobile devices and home businesses," said Sanjay Jha, CEO of Motorola Mobility.

TAMPA, the United States, June 18 (Xinhua) -- The HIV/AIDS patients in the U.S. state of Florida are in dispute with state authorities over a proposal to impose tighter restrictions on those who qualify for drugs provided by the state's AIDS Drug Assistance Program (ADAP).According to the proposed restrictions, individuals would have to earn less than 21,000 U.S. dollars annually to qualify for ADAP drugs. If approved by the Florida Department of Health (FDH), this would affect approximately 1,150 HIV/AIDS patients."The FDH is currently looking at the number of cost containment activities, including altering the financial eligibility for ADAP services," said FDH's press secretary Jessica Hammonds. "After soliciting public input on this matter, the department is in the final stages of evaluating the matter."The Florida ADAP program serves almost 9,500 clients, each of whom receiving 8,600 dollars in funding annually, Hammonds said. There are still another 3,482 on a waiting list.Four FDH sponsored public hearings were held in April and May on the proposal to reduce HIV/AIDS funding. Two were held in Miami, one in Tampa, and the other one was held in the state capital city of Tallahassee. Over 1,000 people attended the hearings.The issue has become so ubiquitous that it caught the attention of the Elton John AIDS Foundation (EJAF), created by the popular entertainer of the same name.

BEIJING, Sep. 13 (Xinhuanet) --Experts have called for a national drug-control system after a nationwide deficit of a life-saving drug, which has lasted at least three months.Doctors at a Beijing hospital said some specialized hospitals, which perform hundreds of cardiac operations every month, have been paralyzed by their lack of protamine sulfate, which is commonly administered after heart surgery to reverse the anticoagulant effects of heparin.The earliest report of a shortage was in Hubei province on July 21. This was followed by reports of shortages in Guangdong, Shandong and Liaoning provinces.The Shandong newspaper, Qilu Evening News, quoted a regional sales manager, surnamed Zhuang, as saying the province had been allocated 150 doses of protamine sulfate after Shanghai No 1 Biochemical and Pharmaceutical Co Ltd recently resumed production of the drug."But its monthly use here is usually 10,000 doses," he said.The Ministry of Health has denied it is responsible for supplies of the drug and passed the buck to the State Food and Drug Administration, claiming the latter is responsible for the supervision of medicines.Shen Chen, head of the publicity office of the State Food and Drug Administration, said he was unaware of the shortage, but said the administration is responsible for the quality of medicines, not the supply."Development and reform authorities oversee the medicines' prices, while the industrial and commercial authorities oversee the storage. The food and drug departments only cover the approval and quality of medicines."Industry insiders said one of the reasons for the shortage was the low profit margin, which discourages companies from mass producing the drug."Some companies can't earn enough to recover their costs, therefore it is almost impossible to maintain their enthusiasm for continuing production," said Lu Guoping, secretary-general of the Shanghai Pharmaceutical Trade Association.Lu said the government should issue policies to prevent future shortages of such medicines to avoid possible nationwide public health incidents.Yi Shenghua, a lawyer at Beijing Yingke Law Firm, said the country should have a unified system to guarantee the normal supply of medicines that are widely used and drug manufacturers should fulfill their responsibilities to society, even though there is no law stipulating they should produce specific medicines.He came up with two ways to deal with the problem of companies only producing profitable drugs."The government can order businesses to manufacture a certain amount of cheap medicines. Or it can offer financial assistance to subsidize cheap, but life-saving medicines."